Accessibility Menu
Acarix Ab (publ) logo

Acarix Ab (publ)(OTC) ACIXF

Current Price$0.02
Market Cap$24.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-38%
5 YearN/A
1 Year-49%
1 Month-25%
Acarix Ab (publ) last closing stock price
MetricPriceDate
Last closeUSD 0.022026-07-21
Acarix Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.31%USD 0.032026-07-13
1 month-24.83%USD 0.032026-06-16
3 month-37.71%USD 0.042026-04-20
Year to date-28.41%USD 0.032025-12-26
1 year-49.3%USD 0.042025-07-21
3 year-20.69%USD 0.032023-06-16
Since inception-37.71%USD 0.042022-12-07

Acarix Ab (publ) Financials at a Glance

Market Cap

$24.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 8.04M

Net Income (TTM)

-SEK 42.70M

EPS (TTM)

-$0.00

P/E Ratio

-5.45

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.02

Volume

500,000

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.02 - $0.04

Estimated Earnings Date

Aug 13, 2026

ACIXF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Acarix Ab (publ)

Acarix AB (publ) is a medical technology company focused on developing AI-powered diagnostic tools for the assessment of coronary artery disease (CAD). The company aims to enhance patient care through innovative solutions, primarily the CADScor System, which utilizes advanced acoustic measurements and AI algorithms.

Products and Services
  • CADScor System for immediate CAD assessment
  • AI-driven diagnostic tools for healthcare providers
  • International deployment of medical technology solutions
Growth Outlook
  • Strong demand for CAD diagnostics in healthcare markets
  • Expansion plans targeting international markets
  • Continued investment in R&D to enhance product offerings
Financial Highlights
  • Recent quarterly revenue of 2,415,782 SEK, showing growth potential
  • Cash and cash equivalents of 25,705,639 SEK as of March 2026
  • Current ratio of 5.72 indicates strong liquidity position
Acarix AB operates in the healthcare sector, specifically within medical devices, and is headquartered in Malmö, Sweden. The CADScor System represents a significant advancement in the early detection of CAD, which is a leading cause of morbidity and mortality worldwide. The company's focus on AI technology positions it well within a rapidly evolving medical landscape. The growth outlook for Acarix is promising, driven by increasing global awareness of CAD and the need for efficient diagnostic tools. The company's strategic initiatives to expand into international markets and invest in research and development are expected to bolster its market presence and product capabilities. Financially, Acarix has demonstrated resilience with a recent quarterly revenue of 2,415,782 SEK, reflecting its ability to generate income despite the challenges faced in the medical technology sector. The company's liquidity is strong, with cash and cash equivalents amounting to 25,705,639 SEK, providing a solid foundation for future growth initiatives. The current ratio of 5.72 further underscores the company's capacity to meet short-term obligations, indicating a robust financial health. Overall, Acarix AB presents an intriguing opportunity for investors interested in the medical technology sector, particularly in innovative solutions for coronary artery disease diagnostics.
AI Generated • Jul 18, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

8

CEO

Aamir Mahmood, MBA

Website

www.acarix.com

Headquarters

Malmö, SN 211 19, SE

ACIXF Financials

Key Financial Metrics (TTM)

Gross Margin

65.62%

Operating Margin

-526.78%

Net Income Margin

-530.88%

Return on Equity

-106.02%

Return on Capital

-125.78%

Return on Assets

-98.30%

Earnings Yield

-18.35%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$24.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.12B

Volume

500.00K

Avg. Volume

20.91K

Financials (TTM)

Gross Profit

SEK 5.28M

Operating Income

-SEK 42.37M

EBITDA

-SEK 38.47M

Operating Cash Flow

-SEK 35.56M

Capital Expenditure

-SEK 1.77M

Free Cash Flow

-SEK 36.22M

Cash & ST Invst.

SEK 25.71M

Total Debt

SEK 0.00

Acarix Ab (publ) Performance Analysis

Acarix Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 575,30331.4%
20232023-12-31SEK 587,8892.2%
20242024-12-31SEK 586,603-0.2%
20252025-12-31SEK 750,54727.9%
Acarix Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-34.1%
Q32025-09-30106.1%
Q42025-12-31-9.1%
Q12026-03-3113.1%
Acarix Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK -0.03-22.7%
20232023-12-31SEK -0.02-43.6%
20242024-12-31SEK -0.01-55.8%
20252025-12-31SEK -0.00-35.3%
Acarix Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-309.5%
Q32025-09-3012.3%
Q42025-12-31-1.0%
Q12026-03-311.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

SEK 2.42M

+39.7%

Gross Profit

SEK 1.31M

-6.6%

Gross Margin

54.33%

N/A

Market Cap

$24.49MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.06M

N/A

Employees

8

N/A

Net Income

-SEK 8.75M

+38.0%

EBITDA

-SEK 7.78M

+40.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

SEK 25.71M

-42.9%

Total Debt

SEK 0.00

N/A

Accounts Receivable

SEK 5.39M

+19.5%

Inventory

SEK 6.23M

-2.7%

Long Term Debt

SEK 0.00

N/A

Short Term Debt

SEK 0.00

N/A

Return on Assets

-98.30%

N/A

Return on Invested Capital

-1.15%

N/A

Free Cash Flow

SEK 1.11M

+109.5%

Operating Cash Flow

SEK 1.11M

+109.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BAKPFCondor Energy Limited
$0.01+0.00%
RHEPRegional Health Properties, Inc.
$1.01+0.00%
VIFIVie Financial Group, Inc.
$0.00+0.00%
SMVISocial Media Ventures, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
NUNu Holdings
$14.09-0.01%

Questions About ACIXF

What is the current price of Acarix Ab (publ)?

Acarix Ab (publ) is trading at $0.02 per share.

What is the 52-week range for Acarix Ab (publ)?

Over the past 52 weeks, Acarix Ab (publ) has traded between $0.02 and $0.04.

How much debt does Acarix Ab (publ) have?

As of the most recent reporting period, Acarix Ab (publ) reported total debt of SEK 0.00.

How much cash does Acarix Ab (publ) have on hand?

Acarix Ab (publ) reported SEK 2.71M in cash and cash equivalents in its most recent financial results.

What is Acarix Ab (publ)’s dividend yield?

Acarix Ab (publ) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services